Biocon Limited Launches Liraglutide in UK for Diabetes and Obesity

Biocon Limited ( (IN:BIOCON) ) has shared an update.

Biocon Limited has launched its Glucagon-like peptide-1 (GLP-1) drug, Liraglutide, in the United Kingdom for diabetes and obesity treatment, following approval from the Medicines and Healthcare Products Regulatory Agency (MHRA). This launch marks Biocon as the first generics company to receive such approval in a major regulated market, highlighting its scientific and manufacturing capabilities. The introduction of Liraglutide in the UK is a strategic move to make the drug more accessible and affordable, addressing an unmet healthcare need. Biocon plans to expand the reach of this drug into other European markets, the U.S., and select geographies, reinforcing its position as a key player in GLP-1 therapies.

More about Biocon Limited

Biocon Limited is an innovation-led global biopharmaceutical company that focuses on developing affordable healthcare solutions. It specializes in the production of complex generics, biosimilars, and novel biologics, with a significant emphasis on enhancing healthcare outcomes globally.

YTD Price Performance: -12.93%

Average Trading Volume: 175,290

Current Market Cap: 385.5B INR

For detailed information about BIOCON stock, go to TipRanks’ Stock Analysis page.